UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Myofilament Calcium Sensitivity: Mechanistic Insight into TnI Ser-23/24 and Ser-150 Phosphorylation Integration

Frontiers in physiology, 2016, Vol.7, p.567

2016

Volltextzugriff (PDF)

COVID‐19 and the adaptive evolution of genetic counseling

Journal of genetic counseling, 2022-08, Vol.31 (4), p.832-835

2022

Volltextzugriff (PDF)

Cardiac troponin I tyrosine 26 phosphorylation decreases myofilament Ca2+ sensitivity and accelerates deactivation

Journal of molecular and cellular cardiology, 2014-11, Vol.76, p.257-264

2014

Volltextzugriff (PDF)

Cardiac Troponin I Ser-23/24 and Tyr-26 Phosphorylation Crosstalk

Biophysical journal, 2015-01, Vol.108 (2), p.597a-598a

2015

Volltextzugriff (PDF)

Cardiac troponin I tyrosine 26 phosphorylation decreases myofilament Ca 2 + sensitivity and accelerates deactivation

Journal of molecular and cellular cardiology, 2014, Vol.76, p.257-264

2014

Volltextzugriff (PDF)

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

The New England journal of medicine, 2021-09, Vol.385 (13), p.1196-1206

2021

Volltextzugriff (PDF)

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Annals of oncology, 2024-03, Vol.35 (3), p.317-326

2024

Volltextzugriff (PDF)

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

The New England journal of medicine, 2012-07, Vol.367 (2), p.107-114

2012

Volltextzugriff (PDF)

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Nature medicine, 2022-11, Vol.28 (11), p.2364-2373

2022

Volltextzugriff (PDF)

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

European journal of cancer (1990), 2019-03, Vol.109, p.61-69

2019

Volltextzugriff (PDF)

Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action

Journal of investigative dermatology, 2024-07

2024

Volltextzugriff (PDF)

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

The New England journal of medicine, 2023-12, Vol.389 (24), p.2256-2266

2023

Volltextzugriff (PDF)

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

Journal for immunotherapy of cancer, 2024-06, Vol.12 (6), p.e009028

2024

Volltextzugriff (PDF)

823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

Annals of oncology, 2022-09, Vol.33, p.S924

2022

Volltextzugriff (PDF)

LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial

Annals of oncology, 2023-10, Vol.34, p.S1289-S1290

2023

Volltextzugriff (PDF)

Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report

Cerebellum (London, England), 2023-02, Vol.22 (1), p.26-36

2023

Volltextzugriff (PDF)

64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)

Annals of oncology, 2020-12, Vol.31, p.S1442-S1443

2020

Volltextzugriff (PDF)

Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT002-CT002

2021

Volltextzugriff (PDF)

Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma

Annals of oncology, 2017-09, Vol.28, p.v435-v435

2017

Volltextzugriff (PDF)

Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1035-1035

2023

Volltextzugriff (PDF)

Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT223-CT223

2023

Volltextzugriff (PDF)

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF V600E/K mutant advanced or metastatic melanoma (MM)

Journal of clinical oncology, 2012-06, Vol.30 (18_suppl), p.LBA8509-LBA8509

2012

Volltextzugriff (PDF)

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.LBA8509-LBA8509

2012

Volltextzugriff (PDF)

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

The New England journal of medicine, 2012, Vol.367 (2), p.107-114

2012

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(8)
Melanoma
(7)
Metastasis
(6)
Adult
(5)
Metastases
(5)
Oncology
(5)
Patients
(5)
Dacarbazine
(4)
Melanoma - Drug Therapy
(4)
T Cell Receptors
(4)
Aged
(3)
Aged, 80 And Over
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Cd3 Antigen
(3)
Female
(3)
Fever
(3)
General & Internal Medicine
(3)
Lymphocytes T
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Myofilament Calcium Sensitivity: Mechanistic Insight into TnI Ser-23/24 and Ser-150 Phosphorylation Integration

COVID‐19 and the adaptive evolution of genetic counseling

Cardiac troponin I tyrosine 26 phosphorylation decreases myofilament Ca2+ sensitivity and accelerates deactivation

Cardiac Troponin I Ser-23/24 and Tyr-26 Phosphorylation Crosstalk

Cardiac troponin I tyrosine 26 phosphorylation decreases myofilament Ca 2 + sensitivity and accelerates deactivation

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial

Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report

64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)

Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma

Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma

Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF V600E/K mutant advanced or metastatic melanoma (MM)

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF V600/k mutant advanced or metastatic melanoma (MM)

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)

Suchergebnisse filtern